Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Optomed Q2: U-shaped recovery

2020-08-27

14:06

GA

Gergana Almquist

Redeye maintains its valuation of Optomed at base case EUR 8 per share. The company's revenues declined during the lockdowns, but sales are picking up again, and the outlook on Q4 and 2021 is positive.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers